logo
  

Pfizer Invests $120 Million In Four Clinical-stage Biotech Companies In H2 2020 - Quick Facts

Pfizer Inc. (PFE) announced Tuesday that it invested a total of $120 million in four clinical-stage biotech companies during the second half of 2020 as part of the Pfizer Breakthrough Growth Initiative (PBGI).

Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer's scientific expertise to help ensure the continuity of promising clinical development programs of potential future strategic interest to Pfizer.

The first four investments of new program created to support clinical-stage biotechnology companies including companies focused on oncology, rare disease, and inflammation & immunology.

Pfizer invested $10 million in Vancouver, BC-based clinical-stage pharmaceutical company ESSA Pharma (EPIX), $25 million in Cambridge, Mass.-based clinical-stage immuno-oncology company Trillium Therapeutics (TRIL), $25 million in Cambridge, Mass.-based privately held clinical-stage company Vedanta Biosciences, and $60 million in Bedford, Mass.-based clinical-stage genetic medicines company Homology Medicines (FIXX).

Separately, Vedanta Biosciences announced that it intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021. Topline Phase 1 study data showed VE202 was generally safe and well-tolerated at all doses and demonstrated durable and dose-dependent colonization.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,... CVS Health said it has installed time delay safe technology in all 392 Illinois CVS Pharmacy locations, including those in Target stores, to help reduce organized retail crime. The installation of new safes for controlled substances are anticipated to help prevent pharmacy robberies. There is also potential for associated diversion of controlled substance medications, including opioid medications.
Follow RTT